Supernus Pharmaceuticals, Inc.
SUPN
Xếp hạng trong cổ phiếu
#5885
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Giá cổ phiếu
$37.86
Đồng bộ lần cuối: 2026-10-16
Vốn hóa thị trường
$2.20B
Thay đổi (1 ngày)
-4.32%
Thay đổi (1 năm)
-23.08%
Quốc gia
US
Giao dịch Supernus Pharmaceuticals, Inc. (SUPN)
Danh mục
Healthcare
Vốn hóa thị trường của Supernus Pharmaceuticals, Inc.(SUPN)
Vốn hóa thị trường: $2.20B
Tính đến năm October 2026, Supernus Pharmaceuticals, Inc. có vốn hóa thị trường là $2.20B. Theo dữ liệu của chúng tôi, điều này khiến Supernus Pharmaceuticals, Inc. trở thành công ty có giá trị lớn thứ 5885th trên thế giới theo vốn hóa thị trường. Vốn hóa thị trường là tổng giá trị thị trường của tất cả cổ phiếu đang lưu hành của một công ty niêm yết và thường được sử dụng để đo lường giá trị của công ty đó.
Lịch sử vốn hóa thị trường của Supernus Pharmaceuticals, Inc. từ 2018 đến 2026
SUPN So với Top 5 phổ biến nhất stocks
